February 28 – March 1, 2017 | San Francisco

 

 

 

 

Speakers

Expand/Collapse

Brian A. Ference
M.D., MPhil, MSc, FACC, Associate Professor of Medicine; Clinical Chief, Division of Cardiovascular Medicine & Director, Cardiovascular Genomic Research Center
Wayne State University

Brian is a cardiologist and genetic epidemiologist who was educated and trained at Harvard, Yale, Oxford and Cambridge Universities. He is currently Associate Professor of Medicine; Clinical Chief of the Division of Cardiovascular Medicine; and Director of the Cardiovascular Genomic Research Center at Wayne State University. His research focuses on using Mendelian randomization studies 1) to generate naturally randomized evidence to answer clinically relevant questions when a randomized trial would be either impossible or impractical to conduct; 2) to personalize the prevention of cardiovascular disease and 3) to accelerate the drug discovery process by conducting portfolios of naturally randomized genetic trials to validate potential drug targets, inform the design of clinical trial programs and anticipate the results of randomized trials. He is on leave from his current academic post living in Beijing, where he has a license to practice medicine in China and is running a large Precision Medicine genomics project and helping to establish a virtual mobile infrastructure for longitudinal healthcare in China.

Day Two

Wednesday, March 1, 2017

15.45 | Panel Discussion: Addressing the Cost & Complexity of Cardiovascular Trials – An Overview of the Current Challenges & Opportunities in Trial Methodology

13.25 | Beyond Causality: Resolving the Discordance Between Mendelian Randomization Studies & Recent Cardiovascular Outcome Trials

Curtis Rambaran
M.D., FAHA, FRCP, Head of Cardiovascular Translational Medicine
Daiichi-Sankyo

Dr Rambaran received his medical degree from the University of the West Indies in Trinidad and Tobago and completed his residency in Internal Medicine in Yorkshire, UK. He was then awarded the prestigious Wellcome Trust Cardiology Research fellowship at King’s College London to study the ethnic differences in vascular structure and function which produced several publications in JACC, Atherosclerosis, ATVB and Heart. His specialty training in Cardiovascular Medicine and Clinical Pharmacology followed at Guy’s & St Thomas’ hospital, London. He joined the Translational Medicine group at GlaxoSmithKline in 2009 where he worked on novel compounds targeting, vascular inflammation, severe asthma and cardiac disease in COPD. He was subsequently the medical governance lead for the LATITUDE-TIMI 60 Phase 3 outcome study of oral MAPKinase inhibition in ACS subjects. In 2015, he became the European Head of Translational Medicine at Daiichi Sankyo, UK and is presently Head of CV Translational Medicine at Daiichi-Sankyo in New Jersey. His current work focuses on heart failure, stem cell therapy and cardiac safety in drug development.

Day One

Tuesday, February 28, 2017

16.15 | Panel Discussion: What’s Next in the Treatment of Heart Failure?

Eric Green
M.D., Ph.D, Head of Translational Research
MyoKardia, Inc.

Eric Green MD, PhD is a physician-scientist and head of Translational Research at MyoKardia, Inc., a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases. At MyoKardia, he oversees many aspects of preclinical and clinical research. Eric was a senior associate at Third Rock Ventures, where he was involved in launching and building several cardiovascular companies including MyoKardia and Element Sciences. He trained in internal medicine and cardiovascular medicine at Brigham and Women’s Hospital.. Eric was a co-founder of ILab Solutions, a leader in cloud-based laboratory management software, which was acquired by Agilent Technologies, and Respira Design, a medical device company treating asthma in the developing world. He holds an AB in History and Science from Harvard College and an MD and PhD in Chemical and Systems Biology from Stanford University

Day One

Tuesday, February 28, 2017

15.45 | Pioneering Precision Cardiovascular Medicine

Day Two

Wednesday, March 1, 2017

14.25 | Panel Discussion: Potential for Digital Health Technologies to Transform Cardiovascular Trials & Post Marketing Surveillance

Fady I. Malik
M.D., Ph.D, Executive VP, Research & Development
Cytokinetics

Fady I. Malik, M.D., Ph.D., is the Executive Vice President of Research and Development at Cytokinetics, a biotechnology company based in South San Francisco.  Dr. Malik has been with Cytokinetics since its inception in 1998, in a variety of roles, including Vice President, Biology and Therapeutics, all focused towards building the company’s cardiovascular and muscle therapeutic programs.  Since 2000, Dr. Malik has held an appointment in the Cardiology Division of the University of California, San Francisco, where he is currently a Clinical Professor of Medicine and an Attending Interventional Cardiologist at the San Francisco Veterans Administration and UCSF Medical Centers.  Dr. Malik received a B.S. in bioengineering from the University of California at Berkeley, and a M.D./Ph.D. from the University of California at San Francisco where he also completed an internal medicine residency and fellowship in cardiology.

Day Two

Wednesday, March 1, 2017

15.45 | Panel Discussion: Addressing the Cost & Complexity of Cardiovascular Trials – An Overview of the Current Challenges & Opportunities in Trial Methodology

09.25 | Developments in Myosin Activators for the Treatment of Heart Failure

Gregory Schwartz
M.D., Ph.D, Professor of Medicine (Cardiology)
University of Colorado, Denver

Gregory G. Schwartz is Professor of Medicine (Cardiology) at the University of Colorado, Denver. He received a PhD in Physiology and MD from Duke University, served as resident and Chief Resident in Internal Medicine at the University of Colorado, and completed fellowship in Cardiology at the University of California, San Francisco. Dr. Schwartz has served on the faculties of the University of California, San Francisco and University of Colorado since 1988. Dr. Schwartz directs a large animal cardiac physiology laboratory that has been continuously funded by NIH and VA since 1988. The laboratory investigates translational questions in myocardial energy metabolism and ischemic protection. Dr. Schwartz has led and participated in numerous clinical trials focusing on lipid and metabolic interventions in acute coronary syndrome (ACS). These include the first randomized, placebo-controlled outcomes trial of a statin in ACS (JAMA, 2001). Among current activities, Dr. Schwartz is Chair of VA Cooperative Study “VA-IMPACT” evaluating cardiovascular outcomes with metformin in pre-diabetes, and co-Chair of the Odyssey Outcomes trial with alirocumab after acute coronary syndrome.  

Day One

Tuesday, February 28, 2017

13.00 | Panel Discussion: Key Takeaways to Tackle the Future of Cardiovascular Drug Development – Are Cardiometabolics, Cardiorenal & Dyslipidaemia Approaches the Way to Go?

09.30 | Is Metformin a Cardiovascular Drug? – An Overview

Helina Kassahun
M.D., FACC, Senior Medical Scientist in Global Development
Amgen Inc.

Day Two

Wednesday, March 1, 2017

14.25 | Panel Discussion: Potential for Digital Health Technologies to Transform Cardiovascular Trials & Post Marketing Surveillance

Jack W. Reich
Ph.D, CEO & Co-Founder
Renova Therapeutics

Dr. Jack W. Reich has extensive experience in the field of gene therapy. He was a cofounder of the first gene therapy company, Viagene, which was acquired by Chiron. He went on to found Collateral Therapeutics, the first gene therapy company focused on cardiovascular disease, later acquired by Schering AG. Throughout his career, Dr. Reich has had significant interactions with regulatory bodies and has been responsible for regulatory approval and successful introduction of a broad range of new drugs. Dr. Reich received a B.A. in Biology from Washington and Jefferson College, a B.S. in Pharmacy from Creighton University, an M.S. in Hospital Pharmacy Administration from Temple University and a Ph.D. in Pharmaceuticals – International Pharmaceutical Administration from Temple University.

Day One

Tuesday, February 28, 2017

16.15 | Panel Discussion: What’s Next in the Treatment of Heart Failure?

13.45 | Breakthroughs in Heart Failure Treatment – Single-Dose Treatments

Jay Edelberg
M.D., Ph.D, VP & Head, Cardiovascular Development
Sanofi

Jay Edelberg is an M.D., Ph.D graduate of Duke University in Durham, North Carolina. He is a clinical cardiologist and vascular biologist trained at the Massachusetts General Hospital (Internal Medicine), the Beth Israel Deaconess Medical Center in Boston (Cardiovascular Medicine) and Massachusetts Institute of Technology (Biology). From 1999 to 2006, Dr. Edelberg served as coronary care unit (CCU) cardiologist and directed the Cardiac Vascular Biology Research Laboratory at Weill-Cornell Medical Center, with a specific research focus on cardiac stem cells and biomarkers of cardiac aging. In addition, Dr. Edelberg has directed cardiovascular biomarker research at Glaxo Smith Kline and Bristol-Myers Squibb (BMS).  Prior to his current position, Dr. Edelberg was the US Medical Lead for Eliquis at BMS. In 2012 he joined Sanofi as the Vice President and Head of the newly formed PCSK9 Development and Launch Unit. In collaboration with Regeneron Pharmaceuticals, he leads the development of PraluentTM (Alirocumab) and most recently, it was approved by the FDA as the first PCSK9 inhibitor in the US for the treatment of high LDL cholesterol.  Since 2016 Dr. Edelberg has also headed Cardiovascular Development at Sanofi.

Day One

Tuesday, February 28, 2017

13.00 | Panel Discussion: Key Takeaways to Tackle the Future of Cardiovascular Drug Development – Are Cardiometabolics, Cardiorenal & Dyslipidaemia Approaches the Way to Go?

11.00 | An Update on the Current Status of PCSK9 Inhibitor Development

Jim Carr
VP, Clinical Development
Stealth BioTherapeutics

Jim Carr is Vice President of Clinical Development focusing on common and rare diseases in the cardio-renal program at Stealth BioTherapeutics. He brings 20 years of industry experience in the areas of clinical development, medical affairs, lifecycle management, new product planning, and global marketing to Stealth. Previously, Jim was an Executive Director in the Global Cardiovascular Franchise at GlaxoSmithKline. Prior to GlaxoSmithKline, Jim held the role of Vice President of Clinical Development at Arca Biopharma. During Jim’s time in industry, his efforts have centered on cardiovascular drug development, with a specific focus on heart failure. Jim’s educational background is a Doctor of Pharmacy degree from the University of Minnesota and post-graduate training in clinical cardiovascular pharmacology. Prior to joining the pharmaceutical industry, Jim was on the clinical faculty at the University at Buffalo-SUNY School of Pharmacy.

Day One

Tuesday, February 28, 2017

16.15 | Panel Discussion: What’s Next in the Treatment of Heart Failure?

15.15 | Targeting Mitochondria to Improve Outcomes in Heart Failure

Joerg Koglin
M.D., Ph.D, Associate VP, Section Head, Cardiovascular Clinical Research
Merck

Joerg is board-certified in Internal Medicine and Cardiology.  After more than 10 years as an academia-based physician with a junior faculty position at the Department of Cardiology, University of Munich, Germany, Joerg has worked in corporate R&D for over 14 years.  Since joining Merck Research Laboratories in 2007 in the Late Stage Global Clinical Development organization, Joerg has been involved as the Clinical Lead and Development Team Lead in various early and late development programs for atherosclerosis, hypertension, ischemia/reperfusion, thrombosis and atrial fibrillation compounds and supporting the development of novel biomarker platforms to further enhance clinical development of cardiovascular drugs. In his current role, Joerg is Section Head in the Cardiovascular Clinical Research Team providing clinical and medical oversight for all development programs around heart failure and pulmonary hypertension, and supports overall cardiovascular strategy and business development.

Day One

Tuesday, February 28, 2017

16.15 | Panel Discussion: What’s Next in the Treatment of Heart Failure?

14.15 | The Role of sGC Stimulators in the Treatment of Heart Failure

John C. Burnett Jr
M.D., Marriott Family Professor of Cardiovascular Research
Division Of Cardiovascular Diseases, Mayo Clinic

Dr. Burnett is the Marriott Family Professor of Cardiovascular Research, Director of the Cardiorenal Research Laboratory and Mayo Distinguished Investigator.  His research has advanced our understanding of humoral mechanisms in heart failure,  hypertension and cardiometabolic disease with a special focus on the natriuretic peptide/guanylyl cyclase/cGMP pathway.  This research has led to the development of innovative therapeutics and novel diagnostics, which are currently in clinical practice and clinical trials.  Dr. Burnett has been continuously funded by the NIH since 1986 and his 537 publications have been published in leading peer review journals such as New England Journal of Medicine, Science, Circulation, Circulation Research, Journal of the American College of Cardiology, American Journal of Physiology, Proceedings of the National Academy of Science, Kidney International, Hypertension, Clinical Chemistry, Journal Molecular and Cellular Cardiology and European Heart Journal.  He is a member of the prestigious American Society for Clinical Investigation and Association of American Physicians.  Dr. Burnett holds 20 patents and has contributed to the founding of 3 biotechnology companies.

Day One

Tuesday, February 28, 2017

13.00 | Panel Discussion: Key Takeaways to Tackle the Future of Cardiovascular Drug Development – Are Cardiometabolics, Cardiorenal & Dyslipidaemia Approaches the Way to Go?

11.30 | ZD100: A Novel Designer Particulate Guanylyl Cyclase Receptor-An Activating Peptide for Cardiometabolic Disease

John F. Schmedtje Jr.
M.D., MPH, Founder, Coeurative, Inc.; Director
Roanoke Heart Institute

John F. Schmedtje Jr., MD, MPH is founder of Coeurative, Inc. and Director of the Roanoke Heart Institute, a center for clinical investigation, as well as the Virginia Circulation Research Center, a non-profit 501(c)(3) biotech incubator in Roanoke, Virginia. He is a graduate of the Northwestern University Feinberg School of Medicine and the Harvard School of Public Health.

Day Two

Wednesday, March 1, 2017

08.45 | Cardiovascular Hypoxia & Experimental Therapeutics

Joseph C. Wu
M.D., Ph.D, Director, Stanford Cardiovascular Institute, Professor of Medicine
(Cardiology) and Radiology, Stanford School of Medicine

Joseph C. Wu, MD, PhD is Director of the Stanford Cardiovascular Institute and Simon H. Stertzer, MD Professor of Medicine (Cardiology) and Radiology at the Stanford School of Medicine. Dr. Wu received his MD from Yale University School of Medicine. He trained in internal medicine and cardiology at UCLA followed by a PhD in the Dept of Molecular Pharmacology. His clinical interests involve cardiovascular imaging and adult congenital heart disease. Dr. Wu has published >300 manuscripts. His lab works on biological mechanisms of patient-specific and disease-specific induced pluripotent stem cells (iPSCs). The main goals are to (i) understand basic cardiovascular disease mechanisms, (ii) accelerate drug discovery and screening, (iii) develop “clinical trial in a dish” concept, and (iv) implement precision cardiovascular medicine for prevention and treatment of patients. His lab uses a combination of genomics, stem cells, cellular & molecular biology, physiological testing, and molecular imaging technologies to better understand molecular and pathophysiological processes. Dr. Wu has received numerous prestigious awards, including Burroughs Wellcome Fund Career Award for Medical Scientists (2007), National Institutes of Health Director’s New Innovator Award (2008), NIH Roadmap Transformative Award (2009), American Heart Association Innovative Research Award (2009), Presidential Early Career Award for Scientists and Engineers given out by President Obama (2010), AHA Established Investigator Award (2013), and BWF Innovation in Regulatory Science Award (2015).  He also received the Best Basic Science Award in Circulation twice (2006 & 2014), Best Manuscript Award in Circulation Research (2013), and the William Parmley outstanding paper award in JACC (2009). In addition, he received the inaugural Joseph A. Vita Award (2015) at the AHA meeting which is given to an investigator whose body of work published in the last 5 years has had transformative impact on basic, translational, or clinical cardiovascular research. Dr. Wu is an Associate Editor for Circulation Research. He is Senior Guest Editor for JACC: Cardiovascular Imaging. He is also on the editorial board of Journal Clinical Investigator, Circulation Cardiovascular Imaging, Human Gene Therapy, Molecular Therapy, Stem Cell Research, Journal of Nuclear Cardiology, Physiological Genomics, and Scientific Report. He is a council member for the American Society of Clinical Investigation (ASCI), a member of Association of University Cardiologists (AUC), and a member of American Association of Physicians (AAP).  

Day Two

Wednesday, March 1, 2017

10.25 | Patient Specific Stem Cells for Precision Cardiovascular Medicine

Kenneth W. Mahaffey
M.D., Professor of Medicine; Vice Chair of Clinical Research; Director
Stanford Center for Clinical Research (SCCR), Stanford University

Kenneth W. Mahaffey, MD received a bachelor of science in chemistry from Stanford University and a Medical Degree from the University of Washington.  He was a house officer and Chief Medical Resident at the University of Arizona and completed a fellowship in cardiology at Duke University.  He spent 17 years as a faculty member at Duke in the Duke Clinical Research Institute (DCRI), an internationally recognized academic research organization.  He moved to Stanford University in 2013 as the Vice Chair of Clinical Research in the Department of Medicine.  He is also the director of the Stanford Center for Clinical Research (SCCR). Dr. Mahaffey’s primary research interest is the design and conduct of multicenter clinical trials and analyses from large patient databases.  His research focuses on novel antithrombotic agents for the treatment of acute cardiac conditions, the study of agents targeted to protect the myocardium during acute myocardial infarction, and the evaluation of cardiovascular safety of new therapies. Dr. Mahaffey is also interested in the methodology of clinical trials and developing the infrastructure to support researchers to design and conduct efficient impactful clinical investigation.  Current research activities include the growth of SCCR, the standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events, and the evaluating evidenced-based operations in the conduct of large multinational clinical trials. He has authored hundreds of peer-reviewed publications.  He is a fellow in the American College of Cardiology and the American Heart Association.  He is a reviewer for multiple cardiology journals and is an associate editor for the American Heart Journal. Dr. Mahaffey has worked with the FDA and is the chairman of the MI and Death Definitions Working Group which is part of the Standardized Data Collection for Cardiovascular Trials Initiative and is also a consultant for Endocrinologic and Metabolic Drugs Advisory Committee Dr. Mahaffey was a chair of the Duke Institutional Board (IRB) for 10 years and is a member of the Stanford University IRB.

Day One

Tuesday, February 28, 2017

17.00 | Co-Chairs’ Closing Remarks

08.50 | Co-Chairs’ Opening Remarks

Day Two

Wednesday, March 1, 2017

16.45 | Co-Chairs’ Closing Remarks

11.55 | Precision Health: Innovative Approaches

08.00 | Co-Chairs’ Opening Remarks

Mark C. Kowala
Ph.D, CSO, CardioMetabolic and Diabetic Complications Drug Hunting Team
Eli Lilly and Company

Mark C. Kowala PhD is currently Chief Scientific Officer of the CardioMetabolic Drug Hunting Team at Eli Lilly Research Labs in Indianapolis Indiana. He is responsible for leading a team of scientists to discover new small and large molecule therapeutics for the treatment of Cardiovascular Disease.  Dr Kowala joined Lilly in 2007.  Previously he has held positions as Senior Director of the Cardiovascular Discovery Department at Pfizer (2002 -2007) and Senior Research Investigator at Bristol Myers Squibb (1989- 2002). Dr Kowala has 27 years of experience in Cardiovascular Drug Discovery in the Pharmaceutical Industry, he has been involved in the discovery of several compounds that entered clinical trials and has  over 50 publications. Dr Kowala received his BSc (Honors) in 1977 at Monash University, Melbourne Australia and his PhD in 1982 at the Australian National University, Canberra, Australia. He has been a reviewer for several scientific journals, has worked on AHA grant review committees and now is a fund raiser for the AHA. Dr Kowala research interests are molecular signaling pathways of Cardiovascular Disease with an emphasis on understanding their relevance in human disease.

Day One

Tuesday, February 28, 2017

13.00 | Panel Discussion: Key Takeaways to Tackle the Future of Cardiovascular Drug Development – Are Cardiometabolics, Cardiorenal & Dyslipidaemia Approaches the Way to Go?

09.00 | SGLT2 Inhibitors: Cardiorenal Protection & Possible Mechanisms

Matthew T. Roe
M.D., MHS, FACC, Professor of Medicine, Division of Cardiology, Duke University Medical Center,
Faculty Director, Global Outcomes Commercial Mega Trials, Duke Clinical Research Institute (DCRI)

Dr. Matthew T. Roe received his MD degree from Duke University School of Medicine from 1989-1993 and his MHS (Masters of Health Sciences in Clinical Research) degree in 2001 from the same institution. Dr. Roe completed an Internal Medicine residency at Duke University Medical Center from 1993-1996 and a Cardiovascular Fellowship at the Cleveland Clinic Foundation from 1996-1999. Dr. Roe has served as the faculty director of the Global Outcomes Commercial Megatrials group at the DCRI since May, 2013. Dr. Roe has been the principal investigator for numerous phase II-IV cardiovascular clinical trials investigating anti-thrombotic and lipid modifying therapies for acute and chronic cardiovascular disease. Dr. Roe is the co-principal investigator of the ADAPTABLE trial (theaspirinstudy.org) which is the first, large-scale pragmatic trial being conducted in the PCORnet network.  Additionally, Dr. Roe has also served in leadership roles for observational registries focusing upon patients with acute myocardial infarction, patients undergoing percutaneous coronary intervention, and patients with familial hyperlipidemia.

Day One

Tuesday, February 28, 2017

13.00 | Panel Discussion: Key Takeaways to Tackle the Future of Cardiovascular Drug Development – Are Cardiometabolics, Cardiorenal & Dyslipidaemia Approaches the Way to Go?

Day Two

Wednesday, March 1, 2017

14.25 | Panel Discussion: Potential for Digital Health Technologies to Transform Cardiovascular Trials & Post Marketing Surveillance

15.45 | Panel Discussion: Addressing the Cost & Complexity of Cardiovascular Trials – An Overview of the Current Challenges & Opportunities in Trial Methodology

13.55 | ADAPTABLE, the Aspirin Study – A Patient-Centered Trial

Mintu P. Turakhia
M.D. MAS, Assistant Professor, Senior Director of Research & Innovation, Center for Digital Health
Stanford University School of Medicine

Mintu Turakhia M.D. M.A.S. is a cardiac electrophysiologist, outcomes researcher, and Associate Professor of Medicine at Stanford University. In his clinical role, Dr. Turakhia performs invasive procedures, such as catheter ablation and device implantation, to treat heart rhythm disorders. Dr. Turakhia has an active, highly-funded clinical research program in Atrial Fibrillation and runs the scientific program for Stanford’s new Center for Digital Health. He is also the principal investigator of several multi-center trials to test digital health tools and wearable devices to screen and manage heart rhythm disorders and manage drug therapy. Dr. Turakhia is Chief of Cardiac Electrophysiology at VA Palo Alto Health Care System, and a Fellow of the American Heart Association, American College of Cardiology, and Heart Rhythm Society.

Day Two

Wednesday, March 1, 2017

14.25 | Panel Discussion: Potential for Digital Health Technologies to Transform Cardiovascular Trials & Post Marketing Surveillance

Prad Prasoon
Business Technology Strategist, Institute for Precision Cardiovascular Medicine
American Heart Association

Prad serves as the leader for Business Strategies for Emerging Technologies and Strategic Partnerships. In this capacity, he works very closely with the Office of the CEO, the Institute for Precision Cardiovascular Medicine and cross functional AHA leadership and volunteer leadership across the organization  on new emerging areas of focus for American Heart Association including defining and building new strategies enabled and accelerated through technology, data, science and strategic partnerships with a focus on creating a marketplace of precision healthcare solutions for advancing AHA mission.   Prior to AHA, Prad started his career as a consultant working primarily for large multinational organizations like GE both in United States and multiple international locations where he progressively held a variety of roles in strategy planning, execution using technology as the enabler. More recently he was part of the global leadership team at Brink’s Incorporated, a global secured logistics company working on strategies related to their core line of business solutions across 55 countries. He received his degree in computer engineering from University of Mumbai, India and is a certified Six Sigma black belt.  

Day Two

Wednesday, March 1, 2017

11.25 | Precision Cardiovascular Medicine at the American Heart Association

Rooz Sobbi
Ph.D., Senior Research Scientist
TARA Biosystems Inc.

Day Two

Wednesday, March 1, 2017

09.15 | BiowireTM II Platform for the Maturation of Human Engineered Cardiac Tissue for Drug Development, Drug Toxicity and Disease Modeling

Rusty Montgomery
Ph.D, Associate Director, Research
miRagen Therapeutics, Inc.

Rusty Montgomery received his Ph.D. from UT Southwestern in the lab of Eric Olson.  Following a post doc in Eric’s lab, he joined miRagen Therapeutics to translate miRNA discoveries in cardiovascular disease into novel therapeutics.  He is currently Associate Director of Research at miRagen Therapeutics.

Day Two

Wednesday, March 1, 2017

08.15 | Update on the New Developments in the Epigenetic Approach to Treating Cardiovascular Disease

Scott M. Wasserman
M.D., FACC, VP, Global Development, Cardiovascular & Metabolic Therapeutic Area Head, Head of Development Design Center
Amgen Inc.

Dr. Wasserman is the Vice President, Cardiovascular and Metabolic Therapeutic Area Head and Head of the Development Design Center at Amgen. In these roles, he is responsible for the development and execution of the cardiovascular and metabolic strategy and the optimization of clinical development programs across Amgen, respectively. Since joining Amgen in June 2005, Scott has taken new therapies, including small and large molecules, from phase 1 through registration. He set strategy and executed critical global clinical programs in heart failure, anemia, osteoporosis, fracture healing, and lipid metabolism. He led cross-functional teams with representation from discovery, toxicology, clinical pharmacology, statistics, regulatory, safety, development, epidemiology, clinical operations, manufacturing, marketing, value and access, and medical affairs. As Amgen’s first cardiologist, Scott developed the company’s cardiovascular capabilities, shaped its portfolio, and built its Therapeutic Area team.  Over the last 5 years, Scott’s efforts focused on the design and execution of the global Repatha® clinical trials program and registration. Prior to joining Amgen, Scott was on faculty at Stanford University in the Division of Cardiovascular Medicine. At Stanford, he performed research on flow-mediated endothelial gene expression and served as a non-interventional academic cardiologist with expertise in heart failure and echocardiography. He received his M.D., Magna Cum Laude from Harvard Medical School and his B.S., Magna Cum Laude from Haverford College. He completed his postgraduate training in Internal Medicine and Cardiovascular Medicine at Stanford University and did post-doctoral cardiovascular research at COR Therapeutics and Millennium Pharmaceuticals.

Day One

Tuesday, February 28, 2017

17.00 | Co-Chairs’ Closing Remarks

08.50 | Co-Chairs’ Opening Remarks

Day Two

Wednesday, March 1, 2017

16.45 | Co-Chairs’ Closing Remarks

08.00 | Co-Chairs’ Opening Remarks

Thomas Povsic
M.D., Ph.D, Associate Professor of Medicine, Interventional Cardiologist
Duke Clinical Research Institute (DCRI)

Dr. Thomas Povsic MD PhD is an associate professor of medicine and interventional cardiologist in the Duke Clinical Research Institute (DCRI) at Duke University Medical Center. Dr. Povsic’s research experience extends from bench research to phase 3 clinical trials.  His key research interests include the development and translation of novel basic therapeutics to clinical use.  He heads the advanced biomarkers group at the DCRI, focusing on translational research aimed to foster better understanding of mechanisms of action, off target affects, and modulators of efficacy. He has a particular interest in understanding the role of progenitor cell mediated repair on the development of vascular disease and establishing regenerative therapies for treatment of cardiovascular conditions.  He has led a laboratory interested in the assessment of endothelial progenitor cells (EPCs) in a variety of clinical conditions, as well as several clinical trials of regenerative therapies. He was the national principal investigator of the RENEW trial exploring the use of autologous CD34+ cell for the treatment of refractory angina as well as CHART-2, a trial of autologous bone marrow cells augmented for cardiopoiesis for the treatment of congestive heart failure, and is a member of the Transatlantic Alliance for Cell Therapy In Cardiovascular Syndromes (TACTICS group).

Day One

Tuesday, February 28, 2017

16.15 | Panel Discussion: What’s Next in the Treatment of Heart Failure?

Day Two

Wednesday, March 1, 2017

15.45 | Panel Discussion: Addressing the Cost & Complexity of Cardiovascular Trials – An Overview of the Current Challenges & Opportunities in Trial Methodology

10.55 | Hurdles to Bringing Novel Therapies to the Bedside: The example of Auto-CD34+ Cells